pharma · Triple Negative Breast Cancer (TNBC) · Mesothelin-Expressing Tumors · CNTX
Context Therapeutics
Context Therapeutics patent portfolio — 3 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Philadelphia, USA HQ
2015 Founded
26 Employees
Public company Type
CNTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Philadelphia, USA
- Founded
- 2015
- Employees
- 26
- Programs
- 8
- Drugs
- 7
- Patents
- 3
Context Therapeutics patents
3 pharmaceutical patents indexed for Context Therapeutics. 0 expire within 24 months.
Context Therapeutics has 3 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does Context Therapeutics have?
3 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Context Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.